BriaCell Reports Extended Progression-Free Survival To 9.1 Months In ADC Resistant Metastatic Breast Cancer Patient; Top Responder Continues Bria-IMT Treatment In Phase 2 Study
Previously Reported Significant Reduction Of "Eye-Bulging" Tumor; Patient Had Failed 8 Prior Regimens